Back to List View Graph View

Ibrutinib

Ibrutinib is a first-in-class, orally administered small-molecule inhibitor of Bruton's tyrosine kinase (BTK), the signaling enzyme that relays B-cell receptor (BCR) engagement to downstream survival pathways.

Where the papers sit

11 papers from the last 6 months study ibrutinib directly · updated from PubMed 13 Nov 2026

  • BTK Inhibitor Applications

    BTK inhibition is being examined across lymphoma treatment, inflammatory disease, toxicity surveillance, and drug delivery. Resistance recurs through IL-16 production, while uveitis emerges as a possible class effect of ibrutinib and zanubrutinib. Clinical work emphasizes long-term adherence and adverse-event management. Other studies move toward cytokine-based screening and intranasal liposomal delivery for brain tumors, without a single established direction.

    5 papers · 45.5%

  • CLL Treatment Strategies

    CLL treatment is moving toward risk-adapted combinations and cellular therapy rather than uniform early ibrutinib use. Ibrutinib plus venetoclax is being tested for older patients and those with TP53 mutations, while lisocabtagene maraleucel is combined with ibrutinib in relapsed disease. The recurring endpoints are overall response, complete response, progression-free survival, and neutropenia. Early-stage CLL findings continue to define which genetic-risk groups benefit from intervention.

    3 papers · 27.3%

  • Ibrutinib Response Biology

    Ibrutinib sensitivity is being linked to BCR phenotype and to the surrounding tumor microenvironment in large B-cell lymphoma. Cytokine signaling and ECM interactions recur as mechanisms of resistance in three-dimensional models. In HER2-positive metastatic breast cancer, trastuzumab provides the main combination strategy, with immune-cell profiling supporting response assessment. The work remains exploratory, with biomarker-defined benefit and durable clinical activity still unresolved.

    3 papers · 27.3%

PARADIGM SHIFT

Ibrutinib resistance can be imposed by the tumor microenvironment rather than arising solely from tumor-intrinsic genetic escape

The DLBCL decellularized human bone-derived 3D scaffold model and the chronic-ibrutinib-exposed marginal zone lymphoma model (PMIDs 42455448, 42213644) found that ibrutinib sensitivity observed in conventional tumor-cell assays does not reliably predict treatment response in a microenvironmental context. ECM adhesion reduced drug-induced apoptosis in DLBCL cells, while a non-genetic, cytokine-secretory state centered on IL-16 induced cross-resistance across several B-cell lymphoma models and was associated with elevated IL-16 in mutation-negative refractory CLL. The resulting change is to treat extracellular matrix interactions and cytokine-mediated cell-state reprogramming as causal mechanisms of resistance, not merely as secondary correlates or explanations requiring BTK or PLCG2 mutations.

NEW DIRECTION

Ibrutinib is developed as an intranasal, brain-targeted liposomal treatment for glioblastoma

The glioblastoma study treats ibrutinib not as conventional systemic BTK-inhibitor therapy for a B-cell malignancy but as the payload of a pH-sensitive liposomal formulation designed for direct nose-to-brain delivery. By addressing poor solubility, limited bioavailability, and blood–brain barrier permeability through an intranasal delivery system, it assigns ibrutinib a drug-delivery role outside the systemic targeted-treatment and combination-therapy uses represented by the other papers 42184887May.

ibrutinib chemical structure

Papers

The 11 papers from the last 6 months that study ibrutinib directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

BTK Inhibitor Applications (5)
  1. Uveitis as a class effect of Bruton tyrosine kinase inhibitors: ibrutinib and zanubrutinib ocular toxicity. BMJ case reports · 29 Sept 2026 PMID 42810753
  2. High-throughput primary B cell cytokines assay for drug screening in multiple sclerosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 4 Sept 2026 PMID 42697043
  3. Long-Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. European journal of haematology · 14 Aug 2026 PMID 42598870
  4. IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas. Blood · 29 May 2026 PMID 42213644
  5. QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 25 May 2026 PMID 42184887
CLL Treatment Strategies (3)
  1. Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood · 28 Jul 2026 PMID 42520199
  2. First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations. Blood · 16 Jul 2026 PMID 42462092
  3. Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial. Blood · 20 Jun 2026 PMID 42322115
Ibrutinib Response Biology (3)
  1. A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer. Cancer medicine · 27 Jul 2026 PMID 42504645
  2. DLBCL-microenvironment interactions: cytokine profiling and ECM-mediated ibrutinib resistance in a 3D bone-based model. Medical oncology (Northwood, London, England) · 15 Jul 2026 PMID 42455448
  3. The Impact of the BCR Phenotype of Large B-cell Lymphoma on Ibrutinib Sensitivity. Anticancer research · 29 Jun 2026 PMID 42373252

By study type

Clinical trials (4)
  1. Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood · 28 Jul 2026 PMID 42520199
  2. A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer. Cancer medicine · 27 Jul 2026 PMID 42504645
  3. First-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations. Blood · 16 Jul 2026 PMID 42462092
  4. Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial. Blood · 20 Jun 2026 PMID 42322115
Observational studies and case reports (1)
  1. Uveitis as a class effect of Bruton tyrosine kinase inhibitors: ibrutinib and zanubrutinib ocular toxicity. BMJ case reports · 29 Sept 2026 PMID 42810753
Preclinical: animal, cell and lab studies (4)
  1. High-throughput primary B cell cytokines assay for drug screening in multiple sclerosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 4 Sept 2026 PMID 42697043
  2. DLBCL-microenvironment interactions: cytokine profiling and ECM-mediated ibrutinib resistance in a 3D bone-based model. Medical oncology (Northwood, London, England) · 15 Jul 2026 PMID 42455448
  3. The Impact of the BCR Phenotype of Large B-cell Lymphoma on Ibrutinib Sensitivity. Anticancer research · 29 Jun 2026 PMID 42373252
  4. QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 25 May 2026 PMID 42184887
Unclassified: not yet indexed with MeSH (2)
  1. Long-Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib. European journal of haematology · 14 Aug 2026 PMID 42598870
  2. IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas. Blood · 29 May 2026 PMID 42213644